scispace - formally typeset
E

Ehsan Hedayat

Researcher at Tehran University of Medical Sciences

Publications -  5
Citations -  167

Ehsan Hedayat is an academic researcher from Tehran University of Medical Sciences. The author has contributed to research in topics: Common variable immunodeficiency & Primary immunodeficiency. The author has an hindex of 4, co-authored 4 publications receiving 147 citations. Previous affiliations of Ehsan Hedayat include Education and Research Network & Karolinska University Hospital.

Papers
More filters
Journal ArticleDOI

Primary immunodeficiency disorders in Iran: update and new insights from the third report of the national registry.

TL;DR: Registration of Iranian PID patients increased the awareness of medical community of Iran and developed diagnostic and therapeutic techniques across more parts of the country and better estimation of PID in Iran is presented.
Journal ArticleDOI

Rheumatologic complications in a cohort of 227 patients with common variable immunodeficiency.

TL;DR: There was an association between defect in specific antibody responses and negative serologic test results in patients with rheumatologic manifestations and patients with CVID with a history of autoimmunity had lower regulatory T cells counts in comparison with patients without autoimmune disorders.
Journal Article

Morbidity and Mortality of Iranian Patients with Hyper IgM Syndrome: a Clinical Analysis

TL;DR: The molecular mechanism behind the nature of the CSR defective patients in Iran is more compatible with autosomal recessive mutations rather than X-linked HIgM syndrome which is in contrast with other large cohorts of patients with CSR defect.
Journal ArticleDOI

Complications of single growing rod constructs in the treatment of severe early-onset scoliosis: a lesson relearned

TL;DR: Evaluating the complications of single traditional growing rods in the treatment of early-onset scoliosis found the use of single TGRs as the only therapeutic modality should be minimized due to high rate of complications even as a bridge treatment.